Liver dysfunction in patients with IBD under immunosuppressive treatment: Do we need to fear?

Gut

Volumn 59, Issue 10, 2010, Pages 1310-1311

  Beaugerie, Laurent ^a   Gerbes, Alexander L ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; GAMMA GLUTAMYL HYDROLASE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; STEROID; VIRUS RNA;

DISEASE SEVERITY; ENTERITIS; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION TEST; MONOTHERAPY; NOTE; PREVALENCE; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK FACTOR; VIRUS LOAD; VIRUS REPLICATION; COMPLICATION; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; HEPACIVIRUS; INFLAMMATORY BOWEL DISEASES; PHYSIOLOGY; VIRUS ACTIVATION;

DRUG-INDUCED LIVER INJURY; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; VIRUS ACTIVATION;

EID: 77957203043     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.217331     Document Type: Note

References (20)

1. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010;4:28-52.
2. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-25.
3. Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7:80-5.
4. Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol 2009;28:1001-3.
5. Visser K, van der Heijde DM. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol 2009;27:1017-25.
6. Gisbert JP, Luna M, Gonzalez-Lama Y, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007;13:1106-14.
7. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007;102:1518-27.
8. Shaye OA, Yadegari M, Abreu MT, et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and azathioprine (AZA) in adult IBD patients. Am J Gastroenterol 2007;102:2488-94.
9. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003;125:298-303.
10. Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007;56:1404-9.
11. Seksik P, Mary JY, Beaugerie L, et al. Incidence of nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Inflamm Bowel Dis Published online 28 June 2010. doi:10.1002/ibd.21330.
12. Zech CJ, Seiderer J, Reinisch W, et al. Thioguanine-induced nodular regenerative hyperplasia of the liver - ROC analysis of different MR techniques. Eur Radiol 2007;17:1898-905.
13. Laharie D, Vergniol J, Bioulac-Sage P, et al. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver. Eur J Gastroenterol Hepatol 2010;22:487-93.
14. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence based consensus on the prevention, diagnosis and management of opportunistic infections in IBD. J Crohn's Colitis 2009;3:47-91.
15. Loras C, Saro C, Gonzalez-Huix F, et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009;104:57-63.
16. Loras C, Gisbert GP, Minguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010; 59:1340-6.
17. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-6.
18. Cornberg M, Protzer U, Dollinger MM, et al. Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. Z Gastroenterol 2007;45:1281-328.
19. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
20. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-42.